gous knockout mice (eNOS+) develop sustained arterial hypertension. Because of controversy over the development of cardiac pathophysiology in these mice, we undertook to investigate the cardiac functional and biochemical affects of chronic eNOS ablation.
Methods: We examined steady state levels of molecular markers of cardiac hypeltrophy and heart failure in male eNOS." and control mice at 18-20, 27-30, 40 and 52 weeks of age. Histological examination at 40 weeks of age and cardiac functional analysis using the isolated work performing heart preparation were perlormed at 52 weeks of age.
Results: Hearts from eNOS+ mice exhibited concentric left ventricular hypertrophy, multifocal replacement fibrosis and evidence of myocyie degeneration/death. As mice aged, re-induction of atrial natriuretic factor (ANF) and a-skeletal-actin mRNA correlated positively with the degree of cardiac hypertrophy. Significant increases in cardiac expression of tumor necrosis factor-a (TNF-a) mANA and protein were detected at 27-30 weeks.
Sarcoplasmic reticulum
Ca'+-ATPase (SERCA2a) transcript levels were markedly decreased at 27-40 weeks, whereas heads of eNOS"-mice 52 weeks of age demonstrated normalized SERCA2a and slightly decreased phospholamban protein levels.
Although hearts of eNOS'. mice at 52 weeks of age demonstrated no deficit of baseline function, there was a blunted response to P-adrenergic stimulation indicative of reduced contractile reserve.
Conclusions:
Although eNOS+ mice exhibit myocardial remodeling, including re-induction of cardiac fetal genes and dysregulation of TNF-a and SERCA2a, there is no progression to failure before 52 weeks of age and in fact these hearts are hypercontractile.
An increased ratio of SERCA2a protein to phospholamban protein at this timepoint suggests a mechanism for the long-term physiological compensation that occurs in eNOS".
hearts. Methods: TGM and nontransgenic cohorts (NTGM) (20 each) were ovariectomized (0~).
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Slow-release (90 days) estrogen pellets were implanted in 10 mice of each group; the other 10 received placebo. Echocardiograms were performed in awake mice at 2 weeks after ov (baseline) and after 3 months of daily treadmill exercise. LV mass was assessed from M-mode tracings. Mice were then euthanized and some hearts were perfusion-fixed and embedded in paraffin, for sectioning; others were processed for frozen sections and tissue extracts. lmmunohistochemical staining and immunoblotting were performed.
Results: Intact TGM and NTGM had LV masses of 77 and 49 mg. and placebo-treated and estrogen-treated OY TGM had LV masses of 79 and 60 mg. respectively (p-zO.05, for both comparisons). AT-1 receptors, MMP-3 and MMP-13 were increased in untreated ov TGM compared to estrogen-treated OY TGM.
Conclusions:
Estrogen replacement significantly reduced LV mass, AT-1 receptors and MMP-3 and MMP-13 in a model of FHCM. These findings suggest that estrogen can regulate expression of genes involved in matrix metabolism and cardiac fibrosis, which are of clinical importance in human patients with FHCM. There was no difference between the 3 groups for peak heart rate and respiratory quo-
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